Technetium-labeled myocardial perfusion agents

Academic Article

Abstract

  • Since its approval for clinical use in 1975, thallium-201 has been the mainstay for myocardial perfusion imaging to diagnose and manage patients with coronary artery disease. In 1992, 80% of 2.6 million myocardial perfusion imaging studies were done with thallium-201. Thallium-201 has important limitations, however, related to photon energy, half life, and availability. In December 1990, two Tc-99m-labeled agents (sestamibi and teboroxime) were approved for clinical use. There are ongoing clinical trials with other classes of Tc-99m agents. This article describes kinetics and imaging experience with Tc-99m-labeled perfusion agents.
  • Authors

    Published In

  • Cardiology Clinics  Journal
  • Digital Object Identifier (doi)

    Pubmed Id

  • 26916352
  • Author List

  • Heo J; Iskandrian AS
  • Start Page

  • 187
  • End Page

  • 198
  • Volume

  • 12
  • Issue

  • 2